AXIM Biotechnologies, Inc.

Equities

AXIM

US05463V1008

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 20:32:55 27/06/2024 BST			5-day change	1st Jan Change
0.008635 ^USD	+0.41%		+4.88%	-54.74%

05-20	AXIM Biotechnologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-16	AXIM Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

AXIM BIOTECHNOLOGIES, INC. : Change in Directors or Principal Officers (form 8-K)

January 07, 2022 at 09:23 pm

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements with Certain Officers

On January 4, 2022, Mauricio Gatto Bellora tendered his resignation as a member of the Board of Directors of AXIM Biotechnologies, Inc. (the "Company"), and the Company on that date accepted his resignation. Mr. Bellora's decision to resign was not the result of any disagreement with the Company.

Latest news about AXIM Biotechnologies, Inc.

AXIM Biotechnologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-20	CI
AXIM Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-16	CI
AXIM Biotechnologies, Inc. announced that it has received $0.814555 million in funding	03-14	CI
AXIM Biotechnologies, Inc Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation	02-20	CI
AXIM Biotechnologies, Inc. announced that it expects to receive $0.75 million in funding from Medical Marijuana, Inc.	12-25	CI
AXIM Biotechnologies, Inc. Partners With Auer Precision to Scale Assay Production	12-20	CI
AXIM Biotechnologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-20	CI
AXIM Biotechnologies Develops First Non-Invasive, Rapid, Point-Of-Care, Diagnostic Test for Parkinson's Disease	12/09/23	CI
AXIM Biotechnologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	21/08/23	CI
AXIM Biotechnologies, Inc. Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test	01/08/23	CI
AXIM Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide	12/07/23	CI
AXIM Biotechnologies, Inc. announced that it has received $20 million in funding	31/05/23	CI
AXIM Biotechnologies, Inc. Appoints Kurt Phinney as Chief Operating Officer	23/05/23	CI
AXIM Biotechnologies, Inc. announced that it has received $0.575 million in funding	22/05/23	CI
AXIM Biotechnologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	22/05/23	CI
AXIM Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	17/04/23	CI
AXIM Biotechnologies, Inc. Auditor Raises 'Going Concern' Doubt	16/04/23	CI
AXIM Biotechnologies, Inc. Files Patent on Fentanyl Neutralizing Antibody Test, Applies for Drug Enforcement Administration License to Work with Controlled Substance	17/01/23	CI
AXIM Biotechnologies, Inc. Develops Novel Dual IgE/MMP-9 Rapid Ophthalmological Diagnostic Test and Files Provisional Patent	13/12/22	CI
AXIM Biotechnologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
AXIM Biotechnologies, Inc. Receives Initial Order for Diagnostic Solutions as Exclusive Partner Verséa Ophthalmics Commences Initial Commercial Launch	04/10/22	CI
Axim® Biotechnologies Signs Exclusive Global Commercialization Agreement with Verséa™ Ophthalmics for Distribution and Sales of Novel Ophthalmic Diagnostics Solutions	19/09/22	CI
Insider Buy: Axim Biotechnologies	31/08/22	MT
AXIM Biotechnologies, Inc. announced that it has received $0.1 million in funding	28/08/22	CI
AXIM Biotechnologies, Inc. announced that it expects to receive $0.1 million in funding	23/08/22	CI

Chart AXIM Biotechnologies, Inc.

Duration

Period

More charts

Company Profile

Axim Biotechnologies, Inc. is a vertically integrated research and development company. The Company is focused on improving the landscape for the diagnosis of ophthalmological conditions such as dry eye disease (DED) through rapid diagnostic tests. Its core competencies include development of rapid lateral flow immunoassays, reagents, and monoclonal antibody development for such assays. Its product categories include Eye Health, wherein the Company acquired two FDA cleared tests for dye eye disease and has internally developed a third assay; and SARS-CoV-2 neutralizing antibody tests. The Company is focused on developing a proprietary diagnostic platform that can be adapted to test for a variety of analytes including SARS-Cov-2, Lactoferrin, IgE, Lacritin, and MMP-9. Its platform capability can also be applied to rapid testing for vaccine candidates. Its platform can also be used to enable point-of-care detection for one or more cancers using a unique cancer biomarker, QSOX1-L.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AXIM BIOTECHNOLOGIES, INC.	-54.74%	2.53M
MODERNA, INC.	+21.85%	46.93B
LONZA GROUP AG	+37.63%	39.08B
IQVIA HOLDINGS INC.	-8.05%	38.48B
ALNYLAM PHARMACEUTICALS, INC.	+29.04%	31.01B
CELLTRION, INC.	-13.75%	26.14B
ICON PUBLIC LIMITED COMPANY	+10.65%	25.88B
MEDPACE HOLDINGS, INC.	+38.43%	12.53B
BIO-TECHNE CORPORATION	-6.92%	11.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-12.29%	10.65B

Other Biotechnology & Medical Research